 |
|
|
|
 |
|
|
Blanche Alter
|
|
Vernon Ingram, Massachusetts Institute of Technology (MIT)
|
|
Development of methods for measuring hemoglobin synthesis in fetal blood samples, which led to the prenatal diagnosis of hemoglobinopathies (Somatic Cell Genet 1:165, 1975; N Engl J Med 295:1437, 1976), and markedly decreased the incidence of thalassemia in Southern Europe during the subsequent decade.
|
|
|
|
Scott Armstrong
|
|
Stan Korsmeyer, Dana-Farber Cancer Institute (DFCI) - Pathology Dept
|
|
Discovery that mixed-lineage leukemia (MLL) is a unique subtype and that the leukemic cells are dependent on the Flt3 tyrosine kinase for growth and survival, which has led to a trial of Flt3 inhibitors in infant leukemias. (Nat Genet 30:41, 2002; Cancer Cell 3:173, 2003)
|
|
|
|
Bob Baehner
|
|
Manfred Karnovsky, Harvard Medical School (HMS)
|
|
Discovery that an oxidase defect is responsible for chronic granulomatous disease. Science 155:835, 1967; J Clin Invest 48:187, 1969; J Clin Invest 49:865, 1970)
|
|
|
|
Eric Beyer
|
|
Dan Goodenough, HMS
|
|
Discovery and cloning of connexin 43, a major gap junction protein. (J Cell Biol 105:2621, 1987; J Cell Biol 108:595, 1989; Science 243:4895, 1989)
|
|
|
|
Tim Browder
|
|
Judah Folkman, Children's Hospital Boston, Department of Surgery
|
|
Discovery that antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Discovery that low dose chemotherapy can produce an antiangiogenic effect. (Nature 390:404, 1997)
|
|
|
|
Scott Cameron
|
|
Robert Horvitz, MIT
|
|
Discovery of PAG-3, a transcription factor that determines neuroblast fate in C. elegans. (Development 129:1763, 2002). Discovery that phagocytosis promotes cell death in C. elegans. (Nature 412:198, 2001)
|
|
|
|
Jim Croop
|
|
David Housman, MIT
|
|
First cloning of the human multidrug resistance gene. (Cell 47:371, 1986; Nature 323:6090, 1986; Cancer Res 47:5982, 1987)
|
|
|
|
John Curnutte
|
|
Manfred Karnovsky, HMS
|
|
Discovery of cytoplasmic factors involved in superoxide generation that are defective in some patients with chronic granulomatous disease. (J Biol Chem 259:7870, 1984; J Biol Chem 259:11851, 1984)
|
|
|
|
George Daley
|
|
Rudolph Jaenisch, Whitehead Institute, MIT
|
|
Discovery that HoxB4 confers engraftment potential on hematopoietic stem cells (Cell 109:29, 2002) and that HoxB4 can be used in conjunction with nuclear transfer to correct an inherited defect by cloning mouse stem cells, correcting the defect in the stem cells, reprogramming the stem cells to an hematopoietic fate in vitro and using the corrected hematopoietic stem cells to replace the defective bone marrow (Cell 109:17, 2002).
|
|
|
|
Alan D'Andrea
|
|
Harvey Lodish, Whitehead
|
|
Classic discovery and expression cloning of the erythropoietin receptor and discovery that the receptor is constitutively activated by the Friend virus glycoprotein (gp55). (Cell 57:277, 1989; Cell 58:1023, 1989; Nature 343:6260, 1990)
|
|
|
|
David Fisher
|
|
Philip Sharp, MIT
|
|
Construction and characterization of a high affinity DNA binding protein that can displace c-myc. Discovery that DNA bending modifies transcription. (Genes Dev 5:2342, 1991; Cell 72:467, 1993; Nature 373:724, 1995)
|
|
|
|
Jon Fletcher
|
|
Cynthia Morton, Brigham and Women's Hospital
|
|
Development of methods for high frequency cloning of soft tissue tumors and discovery of translocations characteristic of specific tumors. (N Engl J Med 324:436, 1991)
|
|
|
|
Steve Friend
|
|
Robert Weinberg, Whitehead
|
|
Classic discovery and cloning of the retinoblastoma gene (rb), the first tumor suppressor gene. One of the most important discoveries in oncology in the past two decades. Discovery that one copy of the p53 oncogene is mutated in patients with the Li-Fraumeni hereditary cancer syndrome. (Nature 323:643, 1986; Nature 334:124, 1988; Science 250:1233, 1990)
|
|
|
|
Robert Garcea
|
|
Tom Benjamin, HMS
|
|
Characterization of the assembly of polyoma virus. (Proc Natl Acad Sci USA 80:3613, 1983; Virology 160:35, 1983; J Virol 54:311, 1985)
|
|
|
|
Todd Golub
|
|
Gary Gilliland, Brigham and Women's; Howard Hughes Medical Institute
|
|
Discovery and cloning of TEL, a novel ets-like gene. Evidence that TEL/AML1 results from a t[12:21] translocation and is a common rearrangement in myeloid and lymphoid malignancies. (Cell 77:307, 1994; Proc Natl Acad Sci USA 92:4917, 1995)
|
|
|
|
Jed Gorlin
|
|
John Hartwig & Tom Stossel, Brigham and Women's
|
|
Cloning and characterization of the actin binding protein filamin and role in cell motility. (J Cell Biol 111:1089, 1990; Science 255:325, 1992)
|
|
|
|
Steve Grupp
|
|
Abul Abbas, Brigham and Women's
|
|
Identification of proteins associated with membrane IgM in the B cell receptor complex.J Biol Chem 268:25776, 1993; J Exp Med 181:161, 1995)
|
|
|
|
Meredith Irwin
|
|
William Kaelin, DFCI, Adult Oncology
|
|
Discovery that E2F1 induces transcription of a p53-related protein called p73 that is required for E2F1 to induce apoptosis via a p53-independent pathway. (Nature 407:645, 2000; Nature 407:642, 2000)
|
|
|
|
Steven Joffe
|
|
Jane Weeks, Harvard School of Public Health and DFCI
|
|
Characterization of the quality of informed consent in children with cancer. (J Natl Cancer Inst 93:139, 2001, Lancet 358:1772, 2001)
|
|
|
|
Andrew Kung
|
|
David Livingston, DFCI, Adult Oncology, Cancer Biology
|
|
Discovery that monoallelic inactivation of the transcriptional co-activator CREB binding protein (CBP) leads to multilineage defects in hematopoietic differentiation and increased hematopoietic malignancies; that blockade of the interaction between CBP and hypoxia-inducible factor (HIF) diminishes the growth of tumors; and that another transcriptional co-activator, p300, interacts with the nuclear proto-oncogene SYT to help control cell adhesion. (Genes Dev 14:272, 2000; Nat Med 6:1335, 2000; Cell 102:839, 2000; Proc Natl Acad Sci USA 99:5367, 2002)
|
|
|
|
Eric Larsen
|
|
Bruce Furie, Tufts
|
|
Discovery that P-selectin, a platelet adhesive protein, is involved in platelet-phagocyte interactions. (Cell 59:305, 1989; Cell 63:467, 1990)
|
|
|
|
Ronald McCaffrey
|
|
David Baltimore, MIT
|
|
Classic discovery of terminal transferase (TdT) and its utility in the diagnosis of lymphoid neoplasia. Discovery that some patients with CML have lymphoid instead of myeloid blast crises. (Proc Natl Acad Sci USA 70:521, 1973; N Engl J Med 292:775, 1975; N Engl J Med 298:812, 1978)
|
|
|
|
Tom McLean
|
|
Gary Gilliland, Brigham and Women's
|
|
Discovery that TEL/AML1 is the most common chromosomal aberration in pediatric ALL and is associated with a very favorable prognosis. (Blood 88:4252, 1996)
|
|
|
|
Kim Nichols
|
|
Dan Haber, Massachusetts General Hospital
|
|
Identification, by position cloning, of the gene responsible for X-linked lymphoproliferative disease. (Proc Natl Acad Sci USA 95:13765, 1998)
|
|
|
|
Sung-Yun Pai
|
|
I-Cheng Ho, Harvard School of Public Health
|
|
Showed that GATA-3 is indispensable for CD4 thymocyte development, and generally is required for development and maintenance of Th2 lineage cells. (Immunity 19:863, 2003; Proc Natl Acad Sci USA 101:1993, 2004)
|
|
|
|
David Pellman
|
|
Gerald Fink, Whitehead
|
|
Investigation of the role of the TATA element in transcription. Identification and cloning of microtubule-associated proteins required for nuclear division in yeast. (Nature 348:82, 1990; J Cell Biol 130:1373, 1995)
|
|
|
|
Matt Porteus
|
|
David Baltimore, MIT & Cal Tech
|
|
Developed chimeric nucleases for creating double stranded breaks in target genes, which increased gene targeting by up to 2000-fold. (Science 300:763, 2003)
|
|
|
|
Phil Rosoff
|
|
Lewis Cantley, Harvard University
|
|
Development of systems for inducing B-cell differentiation in vitro. (Proc Natl Acad Sci USA 80:7547, 1983; J Biol Chem 259:7056, 1984; J Biol Chem 260:9209, 1985; Cell 40:583, 1985)
|
|
|
|
Mark Rothenberg
|
|
Philip Leder, HMS
|
|
Cloning of eotaxin, a chemokine and eosinophil-selective chemoattractant, and demonstration, by gene deletion that the molecule contributes to antigen-induced eosinophilia. (Proc Natl Acad Sci USA 92:8960, 1995; J Exp Med 181:1211, 1995; Nature Med 2:449, 1996; J Exp Med 185:785, 1997)
|
|
|
|
Alan Schwartz
|
|
Harvey Lodish, Whitehead
|
|
One of the first demonstrations of receptor recycling. (J Biol Chem 257:4230, 1982; J Cell Biol 92:865, 1982; Cell 32:267, 1983)
|
|
|
|
Steve Skapek
|
|
Andrew Lassar, HMS
|
|
Discovery that muscle cell differentiation can be inhibited by cyclin D-dependent mechanisms. (Science 267:1018, 1995; Science 267:1022, 1995; Mol Cell Biol 16:7043, 1996)
|
|
|
|
Alejandro Sweet-Cordero
|
|
Tyler Jacks (MIT)
|
|
Development and characterization of a mouse model for lung cancer (Nat Genet 37:48, 2005)
|
|
|
|
Loren Walensky
|
|
Stan Korsmeyer, DFCI - Pathology Department
|
|
Developed a chemistry technique for synthesizing stabilized, folded peptides and showed that the stabilized activation helix of the proapoptotic protein Bid can kill apoptosis -resistant tumor cells in vitro and in vivo. (Science 305: 1466, 2004)
|
|
|
|
David Williams
|
|
Richard Mulligan, Whitehead
|
|
Classic discovery and first demonstration that modified retroviruses could be used to introduce new genes into hematopoietic stem cells. (Nature 310:476, 1984; Proc Natl Acad Sci USA 83:2566, 1986)
|
|
|
|
Joanne Wolfe
|
|
Jane Weeks, Harvard School of Public Health and DFCI
|
|
Definition of the symptoms and suffering in dying children with cancer, development of a palliative care center, and investigation of how to integrate palliative care with treatment. (N Engl J Med 342:326,2000; JAMA 284:2469, 2000)
|
|
|
